This approval pertains to its utilization in the management of advanced or metastatic breast cancer characterized by ER−positive (ER+), human epidermal growth factor receptor 2-negative (HER2−), and estrogen receptor 1 gene (ESR1) mutations. This evidence concerns the gene ESR1 and breast cancer.